Related by context. All words. (Click for frequent words.) 74 hypersensitivity reactions eg anaphylaxis 71 TEAEs 70 pyrexia mucositis sepsis febrile 69 ocular adverse 69 neutropenia dehydration dyspnea 68 Hypersensitivity reactions 67 treatment emergent adverse 67 neutropenia thrombocytopenia 66 laboratory abnormalities 66 diarrhea nausea vomiting 66 events TEAEs 65 receiving VELCADE 65 receiving XGEVA 65 adverse reactions ≥ 65 Treatment emergent adverse 65 Discontinuations due 64 events SAEs 64 headache nasopharyngitis 64 hematologic adverse 64 events AEs 64 Treatment discontinuations due 64 peripheral sensory neuropathy 64 extrapyramidal symptoms 63 lipid lowering agents 63 headache abdominal pain 63 Adverse events 63 Erythropoietic therapies may 63 ALT flares 63 arterial thromboembolic events 63 nasopharyngitis headache 63 discontinuations due 63 incidence ≥ 63 pancytopenia 62 headache arthralgia 62 hematological toxicities 62 peripheral edema 62 lenalidomide dexamethasone 62 ARCALYST ® 62 constipation nausea 62 events thrombocytopenia neutropenia 62 elevated ALT 62 headache nausea diarrhea 62 FluCAM arm 62 hematological adverse 62 treatment emergent AEs 62 severe hypersensitivity reactions 62 cytopenias 62 nonhematologic adverse reactions 62 hematologic toxicity 62 Infusion Reactions Severe 62 Renal impairment 61 chills fever headache 61 anaphylactic reactions bronchospasm 61 linaclotide treated 61 nasopharyngitis 61 relapsed MM 61 VIIBRYD 61 nausea constipation 61 del 5q MDS 61 runny nose nasal congestion 61 anemia neutropenia 61 mucosal inflammation 61 oxycodone CR 61 Discontinuations 61 thromboembolic events 61 Peripheral edema 61 photosensitivity rash 61 experienced hypomagnesemia 61 CIMZIA TM certolizumab pegol 61 Febrile neutropenia 61 primidone 61 insomnia somnolence 61 lopinavir r arm 61 leucopenia 60 QTc prolongation 60 Serious adverse reactions 60 mcg QD 60 thrombocytopenia neutropenia 60 thrombotic events 60 HMG CoA reductase inhibitors 60 pericardial effusion 60 superficial edema 60 Syndrome RLS 60 somnolence sedation 60 somnolence dizziness 60 angioneurotic edema 60 fatigue asthenia 60 Secondary endpoints 60 ACTEMRA TM 60 myopathy rhabdomyolysis 60 Hypotension 60 Exacerbations 60 desvenlafaxine succinate 60 included exfoliative dermatitis 59 NNT = 59 neutropenia febrile neutropenia 59 Lactic acidosis 59 TMP SMX 59 virologic breakthrough 59 dermatologic reactions 59 paresthesias 59 alpha interferons 59 PR interval prolongation 59 severe exacerbations 59 headache flushing 59 lipid parameters 59 unresectable HCC 59 myalgia arthralgia 59 hepatotoxicity 59 Hematologic 59 QT prolongation 59 intraocular inflammation 59 nausea respiratory distress 59 heparin induced thrombocytopenia 59 neuropsychiatric symptoms 59 DLTs 59 hypomagnesemia 59 anaphylactoid reactions 59 postoperative AF 59 cerebrovascular events 59 didanosine associated 59 Toxicities 59 ß blockers 59 unstable angina pectoris 58 EXJADE 58 symptomatic hyponatremia 58 hallucinations dyskinesia 58 lymphopenia 58 neuropsychiatric adverse 58 diarrhea flatulence 58 Thrombocytopenia 58 unknown etiology 58 retrograde ejaculation 58 Adverse reactions 58 APTIVUS r 58 Serious ocular 58 oral olanzapine 58 intravenous bisphosphonates 58 prednisone prednisolone 58 syncopal 58 thromboembolic 58 hepatic dysfunction 58 leukopenia 58 coinfected patients 58 Primary endpoints 58 HBeAg negative patients 58 thromboembolism 58 Exclusion criteria 58 recurrent DVT 58 acneform rash 58 thrombocytopenia anemia 58 affective psychosis 58 intracranial hemorrhage ICH 58 neutropenia anemia 58 febrile neutropenia 58 Hypertensive adverse reactions 58 bezafibrate 58 ARCOXIA 58 benazepril 58 fluoxetine paroxetine 58 hemorrhagic complications 58 concomitant medications 58 prolonged QT interval 58 tolerability profiles 58 Hypocalcemia 58 endoscopic remission 58 patients receiving ERBITUX 58 tonsillar hypertrophy 58 β blockers 58 Comorbidities 58 headache nausea fatigue 58 mucocutaneous reactions 58 FOLPI 58 salmeterol HFA MDI 57 delayed CINV 57 nonischemic 57 periprocedural 57 discontinuations 57 dopaminergic therapy 57 RAPTIVA 57 Hematologic toxicity 57 haematologic 57 Arrhythmias 57 macrovascular complications 57 HBeAg positive 57 hyperkalemia 57 torsade de pointes 57 neutropaenia 57 bleeding ulceration 57 ventricular tachyarrhythmia 57 refractory gout 57 Thrombotic events 57 neuroleptic malignant syndrome 57 Dyspepsia Tachycardia Myalgia etc. 57 CANCIDAS 57 mild renal insufficiency 57 placebo PBO 57 liver transaminases 57 Hepatotoxicity 57 dose limiting toxicities 57 histologically confirmed 57 Teriflunomide 57 neurologic symptoms 57 certolizumab 57 torsades de pointes 57 hypoglycemic events 57 stage IIIB 57 vomiting abdominal pain 57 adjunctive placebo 57 chronic urticaria 57 hepatic failure 57 constipation dizziness 57 tolterodine 57 oral levofloxacin 57 limiting toxicity 57 COPD exacerbations 57 tardive dyskinesia TD 57 infusion reactions 57 ATACAND 57 Tardive dyskinesia 57 PREZISTA r 57 hemorrhagic cystitis 57 antiretroviral naïve 57 elevated LDH 57 hypoglycaemic episodes 57 hypercalcemia 57 abdominal pain flatulence 56 SAEs 56 neurologic complications 56 Kidney toxicity nephrotoxicity 56 transaminase elevations 56 rash urticaria 56 GLIADEL R Wafer 56 electrolyte abnormalities 56 REYATAZ r arm 56 WARNINGS Myopathy Rhabdomyolysis 56 fatal anaphylactic 56 Neutropenia 56 Ischemic 56 diarrhea headache nausea 56 tipranavir r 56 Severe hypersensitivity reactions 56 dizziness somnolence 56 tapentadol ER 56 nausea diarrhea 56 Brief Psychiatric 56 myocardial infarction stroke 56 electrolyte disturbances 56 somnolence headache 56 RISPERDAL 56 PsA 56 Patients Receiving 56 nephrotoxicity 56 melphalan prednisone 56 Dose limiting toxicities 56 immunosuppressive agents 56 BENICAR HCT 56 antiretroviral naive 56 ECG abnormalities 56 Efficacy endpoints 56 Index CDAI 56 nausea somnolence 56 lipid lowering therapies 56 Torsades de Pointes 56 mycophenolate mofetil 56 Secondary efficacy endpoints 56 dizziness headache nausea 56 non selective NSAIDs 56 pulmonary exacerbations 56 nonfatal MI 56 myelosuppression 56 4mg/kg 56 primary Restless Legs 56 Psoriasis Area 56 gastrointestinal perforation 56 exploratory endpoints 56 diarrhea dyspepsia 56 tumor lysis syndrome 56 vasomotor symptoms 56 symptom flare ups 56 postmarketing adverse 56 elotuzumab 56 RLAI 56 paroxetine sertraline 56 renal insufficiency 56 MEVACOR 56 comorbid conditions 56 Generalized Anxiety Disorder 56 arterial thromboembolic 56 INFERGEN 55 hematological toxicity 55 akathisia 55 fever headaches nausea 55 sensory neuropathy 55 bone marrow suppression 55 oxcarbazepine 55 hematological parameters 55 corticosteroid therapy 55 Somnolence 55 Relapsing Remitting Multiple Sclerosis 55 anemia leukopenia 55 noncardiovascular mortality 55 Baseline characteristics 55 Oral Fingolimod 55 zolmitriptan 55 fatal myocardial infarction 55 ventricular fibrillation VF 55 DETROL LA 55 Postoperative 55 vitreous floaters 55 INVEGA ® 55 unfavorable cytogenetics 55 serum leptin 55 symptomatic pulmonary embolism 55 Serious Adverse Events 55 cholecystitis 55 moderate hepatic impairment 55 headache vomiting 55 renal toxicity 55 antiepileptics 55 nausea dizziness vomiting 55 EEG abnormalities 55 parkinsonian symptoms 55 nonvertebral fracture 55 schizophrenia schizoaffective disorder 55 phonophobia 55 genotypic resistance 55 lipid lowering medications 55 dysmenorrhoea 55 dermatologic toxicities 55 neurologic outcomes 55 plus OBT 55 ZOMIG 55 gastrointestinal toxicities 55 lichen planus 55 LYSTEDA 55 Neuroleptic Malignant Syndrome NMS 55 ACEIs 55 ADCS CGIC 55 diarrhea vomiting nausea 55 KETEK 55 mcg albinterferon alfa 2b 55 fulminant hepatitis 55 Xeloda monotherapy 55 rizatriptan 55 somnolence sleepiness 55 URTI 55 anaphylaxis angioedema 55 pruritis 55 virologic responses 55 REMICADE ® 55 anemia thrombocytopenia 55 clinically meaningful improvements 55 Patients Treated With 55 Dermatologic toxicities 55 orthostatic hypotension 55 beta carotene supplementation 55 EDSS scores 55 impaired renal 55 venous thromboembolic events 55 secondary efficacy endpoints 55 glitazone class 55 lactic acidosis 55 nonaspirin 54 CVD mortality 54 inhaled bronchodilators 54 Stent thrombosis 54 HIV HCV coinfected 54 severe hypoglycemic 54 Sociodemographic 54 receiving ISENTRESS 54 mania hypomania 54 antiplatelet medications 54 resuscitated cardiac arrest 54 KRAS mutant tumors 54 elevated transaminases 54 ST Segment Elevation 54 antiarrhythmic drugs 54 metformin accumulation 54 Subgroup analyzes 54 Pharmacokinetics PK 54 postmenopausal osteoporotic women 54 postoperative infections 54 coadministration 54 Vildagliptin 54 IBDQ 54 nonfatal stroke 54 cSSSIs 54 gemifloxacin 54 HeFH 54 COPEGUS therapy 54 leukotriene receptor antagonists 54 sotalol 54 mg BID 54 PREZISTA ritonavir 54 drowsiness nausea 54 Treated Patients 54 AEs 54 flutamide 54 sore throats nausea 54 gastrointestinal GI bleeding 54 extrapyramidal symptoms EPS 54 multivariate adjustment 54 perioperatively 54 atherothrombotic 54 prospectively stratified 54 pulmonary infiltrates 54 Pediatric Patients 54 β blocker 54 VT VF 54 upper gastrointestinal bleeding 54 REBETOL therapy 54 Elderly Patients 54 anticholinergic effects 54 QT interval prolongation 54 seminomas 54 neutropenic patients 54 concomitant AEDs 54 syncope fainting 54 TNF antagonist 54 microvascular complications 54 Anaphylactic reactions 54 Desvenlafaxine Succinate 54 biochemical relapse 54 Flu Cy 54 neurologic abnormalities 54 INVEGA ™ 54 thrombophlebitis 54 elevated IOP 54 vaginal yeast infections 54 baseline serum creatinine 54 venlafaxine XR 54 Oral mucositis 54 hyperprolactinemia 54 APTIVUS ritonavir 54 recurrent VTE 54 myoclonus 54 EFFEXOR XR 54 antidepressants fluoxetine 54 BEXXAR Therapeutic Regimen 54 LUTS 54 hepatic function 54 polyarticular 54 headache dizziness 53 light headedness dizziness 53 RISPERDAL ® 53 headache nausea dizziness 53 cerebral infarctions 53 elevated creatinine 53 HbA 1c levels 53 amoxicillin clavulanate 53 Allergic reactions 53 TLUS 53 Rituxan infusion 53 hypersensitivity reactions 53 malignancy HCM 53 CV thrombotic 53 GERD migraine headaches 53 serious Interstitial Lung 53 exacerbations 53 acitretin 53 tumor regressions 53 angioedema 53 generalized anxiety disorder GAD 53 â ‰ ¥ 53 cardiovascular thrombotic 53 Entereg R 53 Unstable angina 53 ischemic complications 53 Traficet EN 53 NMDA receptor antagonists 53 quetiapine risperidone 53 KIF6 carriers 53 spinal cord compression 53 urticaria hives 53 metabolic acidosis 53 mu opioid agonist analgesics 53 HF hospitalization 53 TNF blocker therapy 53 P = .# 53 elevated plasma concentrations 53 mg RDEA# 53 placebo controlled clinical trials 53 Complication rates 53 interferon gamma 1b 53 Kaplan Meier estimates 53 coronary revascularization procedures 53 chemotherapy induced neutropenia 53 MULTAQ 53 angiographically 53 intracerebral hemorrhage 53 postintervention 53 #mg BID [001] 53 depressive symptom 53 Non Responders 53 Triptan 53 serologically active patients 53 hypercholesterolemic patients 53 urticaria 53 hypersensitivity allergic reactions 53 tegaserod 53 hyperalgesia 53 demyelinating disease 53 newer antipsychotic medications 53 TDF FTC 53 varicella infection 53 CIMZIA R 53 pamidronate 53 ACTOplus met XR 53 silent ischemia 53 thrombocytopenia 53 analgesic medications 53 vasogenic edema 53 somnolence asthenia infection 53 breast tenderness bloating 53 Chronic Constipation 53 venlafaxine ER 53 hypoglycemic episodes 53 RLS symptoms 53 preintervention 53 confirmed thrombotic cardiovascular 53 abdominal distension 53 Scale EDSS score 53 % CI #.#-#.# [003] 53 Thrombolysis 53 HCV antibody 53 Skin rashes 53 headache nausea 53 baseline HbA1c 53 gastrointestinal disturbances 53 parecoxib 53 drug eluting stent implantation 53 aspartate aminotransferase AST 53 Quetiapine 53 Subtypes 53 AML MDS 53 diarrhea predominant IBS 53 MARINOL R 53 divalproex sodium 53 Shows Efficacy 52 Secondary endpoints included 52 neutropenic sepsis 52 PegIFN RBV 52 androgen deprivation 52 UPDRS motor 52 dizziness sleepiness 52 oral antidiabetes drugs 52 Gastrointestinal GI 52 neurologic dysfunction 52 pentoxifylline 52 every ERBITUX infusion 52 overactive bladder symptoms 52 hypersomnia 52 concurrent ITP 52 cerebrovascular accidents 52 opioid induced 52 Vertebral fractures 52 hypercholesterolaemia 52 warfarin erythromycin 52 Pooled Analysis 52 Hepatic Impairment 52 postoperative morbidity 52 emotional lability 52 recurrent venous thromboembolism 52 hematologic abnormalities 52 hypertensive retinopathy 52 inhaled budesonide 52 QTc interval 52 etiologies 52 intra articular injection 52 Montgomery Asberg Depression 52 overlapping toxicities 52 paliperidone 52 fluoxetine Prozac 52 nausea vomiting constipation 52 external genital lesions 52 arthralgia 52 monoamine oxidase inhibitors MAOIs 52 prucalopride 52 #mg/day [002] 52 Atherosclerotic 52 endometrial hyperplasia 52 neuropsychiatric events 52 AVANDIA 52 cardiovascular ischemic 52 ICD shocks 52 venous thromboembolic disease 52 visceral metastases 52 nausea diarrhea vomiting 52 hemoptysis 52 cardiac conduction 52 ergotamine 52 hematologic parameters 52 flecainide 52 GSK# [001] 52 severe hepatic dysfunction 52 Juvenile Idiopathic Arthritis 52 Cardiotoxicity 52 SSRI SNRI 52 simvastatin ezetimibe 52 Avandia Actos 52 MARINOL ® 52 mg q#h 52 HPA axis suppression 52 thrombotic complications 52 autoimmune reactions 52 cSSSI 52 Cognitive Impairment 52 arterial thrombotic 52 anaphylactoid 52 RRMS patients 52 pharmacokinetic interactions 52 ergot alkaloids 52 histologically proven 52 Disease ILD 52 containing LABAs 52 tiagabine 52 opioid naïve 52 esophageal reflux 52 enterocolitis 52 cardiac valvulopathy 52 Severe infusion 52 comorbidities 52 Adverse effects 52 Coadministration 52 thrombo embolic 52 Serum concentrations 52 thrombotic thrombocytopenic purpura TTP 52 patients evaluable 52 hsCRP levels 52 depression irritability 52 mg Pycnogenol 52 inhibit platelet function 52 gout flare 52 Intracerebral 52 REYATAZ ® 52 autoinflammatory diseases 52 ≥ 52 non hematological toxicities 52 umol L 52 DAS# scores 52 bacteriuria 52 response syndrome SIRS 52 EDARBI 52 apnea hypopnea 52 acromegalic patients 52 ventricular tachyarrhythmias 52 CIPN 52 peginterferon alfa 52 Retrograde ejaculation 52 Partial Response 52 timepoints 52 Depressive Symptoms 52 headaches nausea vomiting 52 Demonstrates Efficacy 52 beta blocker therapy 52 cytopenia 52 cerebrovascular adverse 52 tenderness clinical mastalgia 52 Aromatase Inhibitors 52 1mg dose 52 Auxilium anticipates 52 prolactin elevation 52 event reporting Clintrace 52 PRECiSE 52 danazol 52 frequent awakenings 52 suboptimal adherence 52 posttransplant 52 Sterilization Supplies Markets Independently 51 hypersensitivity reaction 51 System IPSS 51 anticholinergics 51 chronic pancreatitis CP 51 Late Breaker 51 euthymic 51 hormone receptor negative 51 chronic idiopathic thrombocytopenic purpura 51 HAM D# 51 reactogenicity 51 nonresponders 51 pneumonitis 51 % CI #.#-#.# [008] 51 gastrointestinal symptoms 51 BYSTOLIC 51 urinary retention 51 Known hypersensitivity 51 concomitant cardiac 51 extrapyramidal side 51 Paxil paroxetine 51 recurrent ischemia 51 hematologic toxicities 51 severe hepatic insufficiency 51 ischemic cerebrovascular 51 topical corticosteroids 51 generalized epilepsy 51 Demonstrated Significant 51 doxorubicin cyclophosphamide 51 pathologic fractures 51 prolactin levels 51 oxymorphone ER 51 intraoperative complications 51 clinically meaningful improvement 51 Rating Scale MADRS 51 mg/m2 dose 51 Bacterial conjunctivitis 51 reflux symptoms 51 gabapentin Neurontin 51 strong CYP#A# inducers 51 serotonin syndrome 51 conjugated equine estrogen 51 coronary stenoses 51 Subgroup analysis 51 zonisamide SR 51 symptomatic hypotension 51 HIV RNA 51 Dose adjustments 51 erythropoietic 51 Drospirenone 51 PANSS scores 51 CYP #A# 51 insulin detemir 51 Acneform rash occurred 51 confidence interval CI 51 Genetic Variations 51 QTc intervals 51 mg simvastatin 51 Tasigna prolongs 51 ischemic cardiac 51 constipating effects 51 GH deficiency 51 PDE4 inhibitors 51 Chronic hepatitis C 51 thienopyridines 51 epilepsies 51 hypocalcemia 51 Symptom onset 51 #mg/m# [001] 51 NMDA antagonists 51 Cluster headaches 51 hyperbilirubinemia 51 gastrointestinal bleeds 51 clinically meaningful differences 51 bovine thrombin 51 affective disorders 51 hepatic insufficiency 51 -#.# ± [002] 51 Univariate analysis 51 riociguat 51 Selective Serotonin Reuptake Inhibitor 51 fasting insulin 51 Zavesca ® 51 motor tics 51 nasal polyposis 51 pegylated interferon alfa 2b 51 TAXOTERE ® 51 piroxicam 51 inhaled glucocorticoids 51 hypopituitarism 51 HRQL 51 anticoagulant warfarin 51 Rasilez Tekturna 51 anaphylactic reactions 51 Long Term Efficacy 51 tricyclic anti depressants 51 NNRTI resistance 51 multivariate analyzes 51 mitochondrial toxicity 51 plasma pharmacokinetics 51 VcMP 51 Acetaminophen Tylenol 51 Epidemiologic studies 51 symptom severity 51 potassium sparing diuretics 51 CYP#D# inhibitor 51 oral antidiabetic drugs 51 gastrointestinal ulcers 51 Colorectal Cancer Patients 51 paliperidone ER 51 amifostine 51 lumiracoxib 51 neurocognitive functioning 51 despite premedication 51 Nasal polyps 51 somatoform disorders 51 nonsignificant 51 CDAI 51 dosage regimens 51 MMSE scores 51 neuroleptic 51 infrequently occurring 50 toxicities 50 Serotonin syndrome 50 YMRS 50 nonfatal cardiac arrest 50 Androgen Deprivation Therapy 50 MAOIs 50 balsalazide 50 fatigue skin rashes 50 #mg/day [001] 50 severe hypoglycaemia 50 dyspnoea 50 containing abacavir 50 comorbid psychiatric 50 monoamine oxidase inhibitors 50 NIS LL 50 O PPDS 50 Fibrillex TM 50 Il Divo hairstylist Aldo 50 atazanavir ritonavir 50 antirheumatic 50 cobiprostone 50 tonic clonic seizures 50 HAMD 50 CONCERTA ® 50 Telithromycin 50 macroalbuminuria 50 dysrhythmias 50 headache somnolence 50 cranial irradiation 50 primary axillary hyperhidrosis 50 macrovascular disease 50 ACE inhibitors ARBs 50 inhaled anticholinergics 50 SUSTENNA TM 50 painful menstruation 50 nausea photophobia 50 Immunomodulatory 50 T1DM 50 anticholinergic agents 50 MAO inhibitors 50 hypocalcaemia 50 evaluable 50 coronary artery dissection 50 treatment naïve genotype 50 calcaneal fractures 50 alicaforsen enema 50 Tiotropium 50 linear pharmacokinetics 50 Sleep disturbances 50 hyperhydrosis 50 CYP#D# inhibitors 50 Exacerbation 50 virological response 50 ischemic cardiovascular 50 evaluable subjects 50 Glatiramer Acetate 50 Double Blind Randomized 50 Acute pancreatitis 50 serious cardiovascular thrombotic 50 SRBD 50 aspirin NSAIDs 50 adverse cytogenetics 50 ONGLYZA saxagliptin 50 PANSS 50 odds ratios ORs 50 IL 1ß 50 polytherapy 50 neurologic sequelae 50 dyslipidemias 50 liver transplant recipients 50 symptom exacerbation 50 Hypersensitivity 50 spirometric 50 TOPAMAX ® 50 neurocognitive function 50 Randomized Controlled Trials 50 antiepileptic drugs 50 moderately emetogenic 50 carboplatin Taxol 50 triacylglycerol concentrations 50 adenotonsillectomy 50 clinicopathological features 50 PRECAUTIONS Drug Interactions 50 pulmonary exacerbation 50 urate lowering 50 loop diuretics 50 EGFRIs 50 gait disturbance 50 Postmenopausal Women 50 inflammatory biomarkers 50 undergoing peritoneal dialysis 50 Surgical Procedures 50 Severe allergic reactions 50 oral prednisolone 50 INTEGRILIN ® 50 colesevelam 50 hepatic toxicity 50 SGRQ 50 ABC/3TC 50 mu opioid agonists 50 Coronary Artery Calcium 50 heterozygous FH 50 oral antidiabetes 50 MMSE score 50 lopinavir r 50 telithromycin 50 BPS IC 50 severe asthma exacerbations 50 Bcr Abl mutations 50 Adverse Events 50 Placebo Controlled Study 50 mITT population 50 Contraindications 50 Myfortic 50 Magnesium deficiency 50 asthma exacerbation 50 fibrate drugs 50 pharmacodynamic parameters 50 mcg linaclotide 50 cerebral ischemia 50 radiation dermatitis 50 lacosamide 50 depressive symptomatology 50 neurological abnormalities 50 unfavorable variances 50 decompensation 50 tacrolimus ointment 50 cardiac toxicity 50 liver decompensation 50 HUMIRA adalimumab 50 decompensated heart failure 50 prenatal exposures 50 vaccinees 50 acute phosphate nephropathy 50 rhythm disturbances 50 Symptom severity 50 Showed Significant 50 severe hypoglycemia 50 bortezomib refractory 50 vomiting constipation 49 inotropes 49 daytime drowsiness 49 Anticholinergic 49 Scale PANSS 49 olanzapine LAI 49 BENCHMRK 49 treat dysmenorrhea 49 recurrent ischemic 49 torsemide ER 49 symptomatic paroxysmal AF 49 immune dysregulation 49 Oral corticosteroids 49 hemorrhagic colitis 49 NYHA functional class 49 secondary endpoints 49 L lysine 49 beta lactam antibiotic 49 capillary leak 49 hypertension systolic blood 49 mood swings irritability 49 postoperative bleeding 49 abnormal sensations 49 hypomanic episodes 49 elevated bilirubin 49 risperidone olanzapine 49 HbA1c levels 49 nocturnal awakenings 49 atherosclerotic cardiovascular 49 EURIDIS 49 EGFR HER2 49 panitumumab Vectibix 49 APTIVUS 49 FDA defined valvulopathy 49 cerebral ischemic 49 Antiviral Activity 49 prospectively defined 49 menadione 49 Generalised Anxiety Disorder 49 prolonged cytopenias 49 INTEGRILIN 49 oral mTOR inhibitor 49 TELINTRA 49 pulmonary toxicity 49 events ADEs 49 probiotic supplementation 49 neutropenia 49 IPSS 49 Ejection Fraction 49 mycophenolic acid 49 tryptase 49 Hospitalized Patients 49 Telintra 49 nasal symptoms 49 cerebral vasospasm 49 Phase 2a Trial 49 glucose insulin 49 Progressive Multifocal Leukoencephalopathy PML 49 anticonvulsants 49 atypical femur fractures 49 maximal doses 49 electrophysiologic 49 multicenter multinational 49 anticholinergic drugs 49 placebo p = 49 fasting plasma glucose FPG 49 nausea vomiting dizziness 49 Carotid endarterectomy 49 systemic absorption